Precigen Inc - Asset Resilience Ratio
Precigen Inc (PGEN) has an Asset Resilience Ratio of 12.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Precigen Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Precigen Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PGEN total asset value.
Liquid Assets Composition Over Time
This chart breaks down Precigen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Precigen Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $21.88 Million | 12.85% |
| Total Liquid Assets | $21.88 Million | 12.85% |
Asset Resilience Insights
- Moderate Liquidity: Precigen Inc has 12.85% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Precigen Inc Industry Peers by Asset Resilience Ratio
Compare Precigen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Biohaven Ltd.
NYSE:BHVN |
Biotechnology | 16.03% |
|
Galapagos NV
F:GXEA |
Biotechnology | 86.45% |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068 |
Biotechnology | 20.87% |
Annual Asset Resilience Ratio for Precigen Inc (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Precigen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 43.18% | $67.62 Million | $156.62 Million | -3.90pp |
| 2024-12-31 | 47.08% | $68.39 Million | $145.27 Million | +10.48pp |
| 2023-12-31 | 36.60% | $55.28 Million | $151.04 Million | +12.94pp |
| 2022-12-31 | 23.66% | $51.09 Million | $215.98 Million | +3.58pp |
| 2021-12-31 | 20.07% | $72.24 Million | $359.86 Million | +4.71pp |
| 2020-12-31 | 15.36% | $48.33 Million | $314.59 Million | +13.33pp |
| 2019-12-31 | 2.03% | $9.26 Million | $455.76 Million | -14.73pp |
| 2018-12-31 | 16.77% | $120.07 Million | $716.18 Million | +15.40pp |
| 2017-12-31 | 1.36% | $11.56 Million | $846.85 Million | -17.03pp |
| 2016-12-31 | 18.40% | $174.60 Million | $949.07 Million | +7.96pp |
| 2015-12-31 | 10.44% | $102.53 Million | $982.05 Million | -4.92pp |
| 2014-12-31 | 15.36% | $88.50 Million | $576.27 Million | -11.90pp |
| 2013-12-31 | 27.26% | $127.98 Million | $469.47 Million | +27.09pp |
| 2012-12-31 | 0.17% | $260.00K | $151.65 Million | -0.05pp |
| 2011-12-31 | 0.22% | $258.00K | $114.83 Million | -- |
About Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors… Read more